Bimala Devkota
Psychiatric/Mental Health · Lafayette, INNPI 1972984599
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Lundbeck LLC at 24.1% of the total. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $13.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Sunovion Pharmaceuticals Inc.$934
- Otsuka America Pharmaceutical, Inc.$783
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$599
- E.r. Squibb & Sons, L.L.C.$337
- Alkermes, Inc.$336
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,784100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 175 | $1,391 |
| Sunovion Pharmaceuticals Inc. | 46 | $934 |
| Otsuka America Pharmaceutical, Inc. | 40 | $783 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $599 |
| E.r. Squibb & Sons, L.L.C. | 31 | $337 |
| Alkermes, Inc. | 15 | $336 |
| Supernus Pharmaceuticals, Inc. | 19 | $290 |
| AbbVie | 22 | $286 |
| Teva Pharmaceuticals USA, Inc. | 7 | $138 |
| Indivior Inc. | 8 | $135 |
| Corium, LLC | 8 | $93 |
| Biogen | 4 | $85 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| Neurocrine Biosciences, Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Johnson & Johnson | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Tris Pharma Inc | 1 | $23 |
| Neos Therapeutics, LP | 1 | $18 |
| Orexo US, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$5,784 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 52 | $148,014 |
| RexultiBrexpiprazole | 88 | $127,235 |
| IngrezzaValbenazine Tosylate | 12 | $94,348 |
| AristadaAripiprazole Lauroxil | 25 | $94,093 |
| VraylarCariprazine Hcl | 41 | $62,555 |
| TrintellixVortioxetine Hydrobromide | 113 | $54,927 |
| Invega SustennaPaliperidone Palmitate | 13 | $46,164 |
| CaplytaLumateperone Tosylate | 22 | $35,889 |
| VyvanseLisdexamfetamine Dimesylate | 42 | $15,748 |
| Paliperidone ErPaliperidone | 24 | $11,519 |
| FetzimaLevomilnacipran Hcl | 23 | $11,377 |
| BelsomraSuvorexant | 23 | $10,602 |
| Risperidone ErRisperidone Microspheres | 13 | $9,598 |
| AzstarysSerdexmethylphen/Dexmethylphen | 18 | $7,493 |
| Hydroxyzine Hcl | 181 | $3,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $783 | $275,249140 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $52 | $94,34812 claims |
| Alkermes, Inc.Aristada | $336 | $94,09325 claims |
| AbbVieVraylar, Fetzima | $286 | $73,93264 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $16 | $70,675155 claims |
| Johnson & JohnsonInvega Sustenna | $48 | $46,16413 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $599 | $35,88922 claims |
| Corium, LLCAzstarys | $93 | $7,49318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Lafayette
- Christy McLaughlinLafayette$9K
- Hayley KaelinLafayette$8K
- Leann SharpLafayette$7K
- Diana KingLafayette$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.